Sun Pharma's ILUMYA Approved by US FDA for Psoriatic Arthritis Treatment
Sun Pharmaceutical Industries has received US FDA approval to expand the use of its drug ILUMYA (tildrakizumab-asmn) for treating adults with active psoriatic arthritis, in addition to its prior approval for moderate-to-severe plaque psoriasis. The approval is based on positive results from two Phase 3 clinical trials, INSPIRE-1 and INSPIRE-2, which demonstrated the drug's safety and efficacy. ILUMYA is administered by healthcare professionals and may increase infection risk, requiring tuberculosis screening before treatment.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 42/100.
Outlets measured: thefinancialexpress, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–74/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 30 Oct, 04:03 am. Other outlets followed.